ArticleClinical drug investigation2025

Pharmacokinetics, Pharmacodynamics, and Safety Evaluation of the Novel HIF-PH Inhibitor Enarodustat: An Open-Label Phase I Study in Healthy Chinese Participants.

Cheng Cui et al.PubMed ↗Publisher ↗

No numbers read from the abstract.